Skip to main content
. 2023 Nov 22;147(5):1680–1695. doi: 10.1093/brain/awad398

Figure 6.

Figure 6

Elevated plasma IGFBP2 is associated with a greater rate of conversion to Alzheimer’s disease in individuals from the ADNI-1 cohort. Cox proportional hazards models examined the association between baseline plasma IGFBP2 levels and rate of conversion to Alzheimer’s disease (AD). The first quartile and fourth values of plasma IGFBP2 were contrasted. Participants were followed from the baseline visit to the time of diagnosis (of AD), or to the time the participant was last confirmed to be free of AD (mean follow-up, 3.8 years; range, 0.5–16.5 years). Of the 226 individuals that were followed longitudinally, 107 individuals progressed to AD. Individuals with plasma IGFBP2 values in the fourth quartile exhibited a greater rate of conversion to AD, compared with the first quartile. Hazard ratio (HR) and P-values are located in the top right corner. Cox models were adjusted for age, gender and APOE ɛ4 carrier status. ADNI = Alzheimer's Disease Neuroimaging Initiative; IGFBP2 = insulin-like growth factor binding protein-2.